文献速递其他结缔组织病

单核细胞LOXHD1与RHOB表达可预测进行性系统性硬化症相关间质性肺病

Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis-Associated Interstitial Lung Disease.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-01-29

该研究在39例进行性SSc-ILD与43例稳定性SSc-ILD患者的外周血单个核细胞(PBMC)批量RNA中比较基因表达,并在13例进行性、14例稳定性和6例对照者的单细胞RNA中验证。单核细胞LOXHD1和RHOB表达强烈预测疾病进展,RHOB在CD14+与CD16+单核细胞中一致上调,ATXN2L蛋白在进行性患者中下调。作者结论为需在更大规模多中心队列中验证这些候选生物标志物以用于临床决策。

要点

  • 单核细胞LOXHD1与RHOB表达强烈预测SSc-ILD进展。
  • RHOB在CD14+与CD16+单核细胞中一致上调。
  • ATXN2L蛋白在进行性病患者中下调,提示细胞应激反应失调。

核心结论

  • 单核细胞LOXHD1和RHOB表达可强烈预测进行性SSc-ILD,作者结论为下一步需在更大规模多中心队列中验证以用于临床决策。

研究设计与样本

  • 比较既往识别的血清生物标志物、PBMC批量RNA基因表达(39例进行性SSc-ILD与43例稳定性SSc-ILD)及PBMC单细胞RNA基因表达(13例进行性SSc-ILD、14例稳定性SSc-ILD与6例对照者)。

主要发现

  • 既往研究中男性性别、Krebs von den Lungen 6水平与C反应蛋白水平为患者疾病进展的预测因素。
  • 单核细胞LOXHD1与RHOB表达强烈预测疾病进展,提示其在免疫失调中的关键作用。
  • LOXHD1及相关基因富集于炎症基因网络,可能支持患者单核细胞相关炎症。
  • RHOB在单细胞与批量RNA数据的CD14+及CD16+单核细胞中均一致上调,与进行性疾病呈稳健关联。
  • ATXN2L蛋白在进行性疾病患者中下调,提示细胞应激反应失调;S100A12、CHI3L1与MMP9在批量RNA测序及既往微阵列研究中再次与进展相关。

临床怎么用

  • 原文未据此给出推荐,作者结论为下一步需在更大规模多中心队列中验证这些候选生物标志物以用于临床决策。

局限性

  • 作者结论指出需在更大规模多中心队列中验证这些候选生物标志物以用于临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A leading cause of death among patients with scleroderma (SSc), interstitial lung disease (ILD) remains challenging to prognosticate. The discovery of biomarkers that accurately determine which patients would benefit from close monitoring and aggressive therapy would be an essential clinical tool. We aimed to identify gene signatures that would predict progressive ILD. METHODS: We compared previously identified serum biomarkers, bulk peripheral blood mononuclear cell (PBMC) RNA gene expression (39 patients with progressive SSc-ILD and 43 patients with stable SSc-ILD), and single-cell RNA gene expression of PBMC (13 patients with progressive SSc-ILD, 14 patients with stable SSc-ILD, and 6 control participants). RESULTS: In previous studies, male sex, Krebs von den Lungen 6 levels, and C-reactive protein levels were predictors of progressive disease in patients. Monocyte expression of lipoxygenase homology domains 1 (LOXHD1) and Ras homolog gene family, member B (RHOB) strongly predicted progression, suggesting a key role in immune dysregulation. LOXHD1 and related genes were enriched in inflammatory gene networks, which may support monocyte-associated inflammation in patients. RHOB was consistently up-regulated in both CD14+ and CD16+ monocytes across single-cell and bulk RNA data, underscoring robust association with progressive disease. In contrast, ataxin-2-like (ATXN2L) protein was down-regulated in patients with progressive disease, suggesting dysregulation of cellular stress responses. Additionally, S100 calcium-binding protein A12 (S100A12), chitinase-3-like protein 1 (CHI3L1), and matrix metalloproteinase-9 (MMP9), previously linked to tissue remodeling, were again associated with progression in bulk RNA sequencing and previous microarray studies, reinforcing their role in fibrosis. CONCLUSION: With several potential biomarkers of progressive disease in patients, the next step includes validation in larger, multicenter cohorts for use in clinical decision-making.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Padilla CM, Lafyatis R, Gibson KF, et al. Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Care Res (Hoboken). 2026. PMID: 40771159. doi:10.1002/acr.25619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。